Core Viewpoint - The Nasdaq Golden Dragon China Index saw an initial increase of 1.21%, indicating positive market sentiment towards Chinese stocks listed in the U.S. [1] Company Performance - NIO experienced a significant rise of 7.4% - Miniso increased by 5.4% - Yum China rose by 3.4% - Li Auto gained 2.8% - ZTO Express, Zai Lab, Bilibili, Baidu, and Kingsoft Cloud all saw increases of over 2% - Alibaba had a modest increase of 0.7% - Pony.ai declined by 1.2% - New Oriental fell by 2.8% [1] ETF Performance - KWEB ETF rose by 1.14% - CQQQ ETF increased by 0.7% - ASHR ETF decreased by 0.1% - ASHS ETF fell by 1.3% [1]

致：香港交易及結算所有限公司 公司名稱: 再鼎醫藥有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09688 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.000006 USD | | | 30,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.000006 USD | | | 30,000 | 本月底法定/註冊股本總額： USD 30,000 FF ...

Core Viewpoint - The Hong Kong biotechnology sector is experiencing a significant upward trend, with notable gains in various stocks, indicating positive market sentiment in the industry [1] Group 1: Stock Performance - Nocare Biopharma (09969.HK) has seen an increase of over 4% [1] - Other companies such as Zai Lab (09688.HK), WuXi AppTec (02359.HK), WuXi Biologics (02269.HK), and Innovent Biologics (02696.HK) are also witnessing upward movement in their stock prices [1]

Summary of Key Points Core Viewpoint - JPMorgan Chase has increased its stake in Zai Lab Limited (09688) by acquiring 1,920,096 shares at a price of HKD 13.3426 per share, totaling approximately HKD 25.6191 million, resulting in a new holding of about 56,470,300 shares, which represents a 5.04% ownership stake [1][3]. Group 1 - JPMorgan Chase's acquisition of shares indicates a strategic investment in Zai Lab Limited [1][3]. - The total amount spent on the share purchase was approximately HKD 25.6191 million [1][3]. - Following the purchase, JPMorgan's total shareholding in Zai Lab is now approximately 56,470,300 shares [1][3].

Core Viewpoint - Zai Ding Pharmaceutical (09688) announced the issuance of new shares to fulfill stock awards and options under various equity incentive plans [1] Group 1: Share Issuance Details - On February 4, 2026, the company will issue 3.8891 million new shares held by a trustee to fulfill stock awards granted under the 2017, 2022, and 2024 equity incentive plans [1] - Additionally, on the same date, the company will issue 4.6109 million new shares held by a trustee to fulfill stock awards and options granted to executive directors under the 2015, 2017, 2022, and 2024 equity incentive plans [1]

Core Viewpoint - Zai Ding Pharmaceutical (09688) announced the issuance of new shares to fulfill stock incentive plans and options granted to executive directors [1] Group 1: Share Issuance Details - On February 4, 2026, the company will issue 3.8891 million new shares held by a trustee to fulfill the stock awards granted under the 2017, 2022, and 2024 equity incentive plans [1] - Additionally, on the same date, the company will issue 4.6109 million new shares held by a trustee to fulfill the stock awards and options granted to executive directors under the 2015, 2017, 2022, and 2024 equity incentive plans [1]

Group 1 - JPMorgan Chase & Co. increased its stake in Zai Lab Limited (09688.HK) by purchasing 1.9201 million shares at an average price of HKD 13.3426 per share, totaling approximately HKD 25.619 million [1] - Following this acquisition, JPMorgan's total holdings in Zai Lab rose to 56.4703 million shares, increasing its ownership percentage from 4.87% to 5.04% [1]

| 2). 就根據股份計劃授予發行人的董事的股份獎勵或期權而發行新股或轉 | 4,610,920 | 0.41 % | HKD | 0 | | | --- | --- | --- | --- | --- | --- | | 讓庫存股份 - 涉及新股 | | | | | | | 發行新股，由受託人持有，以兌現按先前披露的條款歸屬/行使根據 | | | | | | | 2015，2017，2022及2024年股權激勵計劃向執行董事授出的股份獎 | | | | | | | 勵和期權 | | | | | | | 變動日期 2026年2月4日 | | | | | | | 於下列日期結束時的結存 (註5及6) 2026年2月4日 | 1,128,128,030 | | 0 | | 1,128,128,030 | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | FF305 第 2 頁 共 6 頁 v 1.3.0 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 再鼎醫 ...

Group 1 - Morgan Stanley increased its stake in Zai Lab (09688) by acquiring 1,920,096 shares at a price of HKD 13.3426 per share, totaling approximately HKD 25.6191 million [1] - Following the acquisition, Morgan Stanley's total shareholding in Zai Lab reached approximately 56,470,300 shares, representing a stake of 5.04% [1]

Core Viewpoint - Morgan Stanley increased its stake in Zai Lab (09688) by acquiring 1,920,096 shares at a price of HKD 13.3426 per share, totaling approximately HKD 25.6191 million, raising its ownership to about 56,470,300 shares, which represents 5.04% of the company [1] Group 1 - Morgan Stanley's recent acquisition indicates a positive outlook on Zai Lab's potential growth and market position [1] - The total investment made by Morgan Stanley in this transaction is approximately HKD 25.6191 million [1] - Following the purchase, Morgan Stanley's total shareholding in Zai Lab is now approximately 56,470,300 shares [1] Group 2 - The per-share purchase price of HKD 13.3426 reflects the current valuation of Zai Lab in the market [1] - The increase in ownership percentage to 5.04% may influence market perception and investor confidence in Zai Lab [1] - This transaction highlights the ongoing interest from institutional investors in Zai Lab's stock [1]